claes

/Claes Holmberg

About Claes Holmberg

This author has not yet filled in any details.
So far Claes Holmberg has created 176 blog entries.

Emotra: Agreement with Italian research group

Emotra AB (“Emotra”) is pleased to announce that we have reached an agreement with an Italian research group concerning so-called “research rental”.   181127 - Emotra -Newsletter - Agreement with Italian research group

By | November 28th, 2018|INVESTORS|Comments Off on Emotra: Agreement with Italian research group

Emotra: Psychiatric hospital in London gets started

As Emotra announced in a press release on November 16, a letter of intent has been signed with a London-based psychiatric hospital. The agreement will allow the hospital to evaluate EDOR® in clinical practice for a limited period of time.   181123- Emotra - Newsletter - English hospital gets started

By | November 23rd, 2018|INVESTORS|Comments Off on Emotra: Psychiatric hospital in London gets started

Emotra: Important research study explains the biological mechanism behind EDOR® and hyporeactivity

Emotra is proud to announce that Lars-Håkan Thorell, Emotra’s Head of Research and the inventor of EDOR®, in his research for Emotra has demonstrated the biological mechanism behind hyporeactivity. This discovery explains why an increased suicide risk can be identified by EDOR®.   181120- Emotra - PM - Important discoveries in research

By | November 20th, 2018|INVESTORS|Comments Off on Emotra: Important research study explains the biological mechanism behind EDOR® and hyporeactivity

Emotra signs a letter of intent with a psychiatric hospital in England

Emotra hereby announces that the company has signed a letter of intent with a large, London-based psychiatric hospital. This deal grants the hospital the right to use EDOR® during a limited trial period. The agreement includes 30 tests free of charge, after which Emotra will be compensated for each test analysis.   181116- Emotra - [...]

By | November 16th, 2018|INVESTORS|Comments Off on Emotra signs a letter of intent with a psychiatric hospital in England

Emotra: Successful meetings with psychiatric hospitals

Emotra has recently held a number of meetings with decision-makers who intend to move forward with testing of EDOR® in their regular clinical practice. The psychiatric caregivers that Emotra has met this autumn have grown increasingly aware of how EDOR test results can supplement the diagnoses they make in their clinical examinations.   181114- Emotra [...]

By | November 14th, 2018|INVESTORS|Comments Off on Emotra: Successful meetings with psychiatric hospitals

EMOTRA AB: Resolution on a new rights issue of shares for continued market introduction of EDOR®

Today, November 1, 2018, EMOTRA AB (“Emotra”) announced that its Board of Directors have decided on a new rights issue of shares. This rights issue will comprise a maximum of 23,978,953 shares and the public has also been invited to participate.   181101 - Emotra- PM - Issue resolution

By | November 6th, 2018|INVESTORS|Comments Off on EMOTRA AB: Resolution on a new rights issue of shares for continued market introduction of EDOR®

Management changes at EMOTRA

Emotra’s CEO announces that he is stepping down. Emotra’s board of directors has appointed Marketing Manager Daniel Poté as the new CEO. Daniel will assume this new position immediately. Margit Ferm has stated that she wishes to step down as chairperson of the board, but will continue her engagement as a board member. Claes Holmberg [...]

By | October 24th, 2018|INVESTORS|Comments Off on Management changes at EMOTRA

EMOTRA announces that a German psychiatric hospital is introducing EDOR

Yesterday, on October 17, 2018, Emotra hosted a training seminar for doctors and test leaders at a number of clinics that belong to a German psychiatric and psychotherapeutic hospital. This training is the start of a controlled introduction of the test in their clinical practice. The hospital will borrow hardware from us during a defined [...]

By | October 19th, 2018|INVESTORS|Comments Off on EMOTRA announces that a German psychiatric hospital is introducing EDOR

Important developments for Emotra

Emotra has reached an important stage in its development. A few days ago, a scientific article was published based on a compilation of the results of earlier blind studies. It shows that hyporeactivity is a clear and strong marker for suicide risk. Furthermore, the Company was recently invited by one of Great Britain’s leading chains [...]

By | October 1st, 2018|INVESTORS|Comments Off on Important developments for Emotra